PRESS RELEASE published on 07/01/2024 at 09:22, 2 years 2 months ago Inside Information / Other news releases ABIONYX successfully completes a capital increase of c.€3.4 million through the issuance of shares with warrants. The fundraising aims to strengthen the company's cash position for its development in sepsis and the United States Fundraising Capital Increase Sepsis ABIONYX Shares With Warrants
BRIEF published on 06/27/2024 at 19:27, 2 years 2 months ago ABIONYX Pharma Achieves Unanimous Approval at Combined General Meeting Shareholders Biotech General Meeting Resolutions ABIONYX Pharma
PRESS RELEASE published on 06/27/2024 at 19:22, 2 years 2 months ago Inside Information / Other news releases ABIONYX Pharma announces unanimous approval of all resolutions at its Combined General Meeting. Shareholders renew mandates and approve buyback program Shareholders Buyback Program Renewal Combined General Meeting ABIONYX Pharma
BRIEF published on 06/19/2024 at 21:20, 2 years 3 months ago ABIONYX announces a capital increase without preferential subscription rights Biotechnology Actions United States Increase In Capital Sepsis
PRESS RELEASE published on 06/19/2024 at 21:15, 2 years 3 months ago Inside Information / Other news releases ABIONYX announces capital increase of c.€3.4 million with share issuance and warrants, strengthening financial position for Sepsis and US development, supported by ORSAY 53 investment company Capital Increase Share Issuance ABIONYX Sepsis Development ORSAY 53
BRIEF published on 06/13/2024 at 19:53, 2 years 3 months ago ABIONYX Pharma Receives FDA Approval for New Sepsis Study FDA Clinical Study ABIONYX Pharma Sepsis CER-001
PRESS RELEASE published on 06/13/2024 at 19:48, 2 years 3 months ago Inside Information / Other news releases ABIONYX Pharma completes successful pre-IND meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial in Sepsis, marking significant progress in developing innovative therapy FDA ABIONYX Pharma Sepsis CER-001 Pre-IND Meeting
Published on 09/23/2026 at 22:00, 4 hours 23 minutes ago Petrolympic Adopts Semi-Annual Financial Reporting
Published on 09/23/2026 at 18:25, 7 hours 58 minutes ago Boba Mint Holdings Ltd. Reports Strong Early Subscription Adoption Following Soft Launch of Amino Pro
Published on 09/23/2026 at 15:42, 10 hours 41 minutes ago Global Atomic Announces C$50 Million Public Offering of Units
Published on 09/23/2026 at 14:31, 11 hours 52 minutes ago First Breach Completes First Untethered Flight of Proprietary Drone Prototype, Advancing American-Made Unmanned Systems Program
Published on 09/23/2026 at 14:30, 11 hours 53 minutes ago Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
Published on 09/23/2026 at 23:00, 3 hours 23 minutes ago Correction of a release from 23.09.2026 18:00 CET/CEST - MHM CORPORATE ANNOUNCES THE SUCCESS OF ITS CAPITAL INCREASE WITH PREFERENTIAL SUBSCRIPTION RIGHTS AND THE PARTIAL EARLY REDEMPTION OF BONDS REDEEMABLE IN SHARES
Published on 09/23/2026 at 19:51, 6 hours 32 minutes ago LIGHTON: LightOn renews its bond financing with the same financial partners for a maximum nominal amount of €4 million, and thus extends its cash flow horizon
Published on 09/23/2026 at 18:05, 8 hours 18 minutes ago XPRIZE Wildfire Awards $4.55M to Innovators Advancing Wildfire Detection and Response
Published on 09/23/2026 at 18:00, 8 hours 23 minutes ago ARVERNE GROUP: Release of the 2026 half-year financial report
Published on 09/23/2026 at 18:00, 8 hours 23 minutes ago ARVERNE GROUP: First half of 2026 60.1% growth in gross business volume to €16.8 million Operational performance above expectations
Published on 09/23/2026 at 19:14, 7 hours 9 minutes ago Robust performance from Investments and continued execution of the strategy
Published on 09/23/2026 at 17:45, 8 hours 38 minutes ago Report on share repurchases from 16 to 21 September 2026
Published on 09/23/2026 at 17:45, 8 hours 38 minutes ago Infotel : H1 2026 RESULTS. Revenue growth of +9.4%.
